PTAB: Unidirectional Language of AIA Estoppel Dooms Common-Law Claim Preclusion Argument Based on District Court’s Final Judgment of No Invalidity

July 24, 2023

Reading Time : 2 min

By: Caitlin E. Olwell, Rubén H. Muñoz, Ange Christiani (Law Clerk)

The Patent Trial and Appeal Board has denied a patent owner’s motion to terminate an inter partes review proceeding finding that the unidirectional nature of estoppel under 35 U.S.C. § 315(e) renders common-law claim preclusion inapplicable as a basis for termination.

Patent Owner moved to terminate an IPR after Petitioner successfully joined the proceeding, which was originally filed by another party. Because Petitioner had unsuccessfully litigated invalidity of the patent in district court, Patent Owner argued that termination was proper on a theory of claim preclusion. The district court had issued a final judgment of no invalidity after Patent Owner and Petitioner had fully and fairly argued their cases. Petitioner’s joinder in the IPR, Patent Owner alleged, was nothing more than a collateral attack on the final judgment. Petitioner responded that common-law claim preclusion does not apply to IPRs due to differing burdens of proof between district court actions and IPRs, and the proceedings lacking the same nucleus of operative facts. 

While the Board ultimately decided in favor of Petitioner, it shored up its analysis on three prongs of support: (1) the opinion of the Court in Astoria Fed. Sav. & Loan Ass’n v. Solimino, 501 U.S. 104 (1991), (2) the explicit language in the AIA, 35 U.S.C. § 315(e) and (3) the Congressional intent in passing 35 U.S.C. § 315(e). 

First, the Board found that contrary to Patent Owner’s interpretation, Astoria stood for the premise that the presumption of common-law preclusion exists only as far as “Congress has failed to expressly or impliedly evince any intention on the issue.”

Second, the Board dissected the language of 35 U.S.C. § 315(e) and found that it exhibits a one-way avenue. According to the Board, Section 315(e) states that following a final written decision, the petitioner in an IPR “may not request or maintain a proceeding before the Office,” nor “assert either in a civil action…or in a proceeding before the ITC” a challenge to a claim on a ground petitioner “raised or reasonably could have raised during the inter partes review.” The Board further noted that the statute is silent on the reverse scenario: a party in a fully-litigated district court action later challenging the same claim on the same grounds in an IPR.

Third, the Board concluded that Congress’ act of passing the AIA, which contained its own specific estoppel provisions, “evinced” the intention that common-law claim preclusion was superseded. The Board determined that existence of different burdens of proof between IPRs and district court actions, the removal of the dual-directional language from the predecessor statute to IPR (inter partes reexamination (35 U.S.C. § 317)) and the need to give effect to § 315—which would become redundant if interpreted to be multi-directional—all evidenced Congress’ intent for IPR estoppel as a unidirectional barricade.

Practice Tip: With its one-way estoppel provision confirmed by at least one PTAB panel, the AIA appears to provide patent challengers a second bite at the apple in an IPR proceeding. After receiving a final judgment in district court, patent challengers who fail to prove invalidity by clear-and-convincing evidence may not be precluded from bringing the same claims and evidence against a patentee under a lower burden of proof, and should consider this avenue as a viable option in their overall litigation strategy.

OpenSky Indus. v. VLSI Tech. LLC, IPR2021-01064, Paper 132 (P.T.A.B. Apr. 4, 2023)

Share This Insight

Previous Entries

IP Newsflash

November 3, 2025

The Federal Circuit recently clarified the requirement for work disclosed in a reference to qualify as “by another” under pre-AIA Sections 102(a) and (e), holding that there must be complete inventive identity between the information disclosed in the asserted reference and the inventors named on the relevant patent. 

...

Read More

IP Newsflash

October 31, 2025

The District Court for the Northern District of California recently granted a defendant’s motion to bifurcate, ordering that issues related to PGR estoppel should be decided in a bench trial, while the remaining issues in the case should proceed to a jury trial.

...

Read More

IP Newsflash

October 31, 2025

The Northern District of Iowa recently held that a defendant’s motion for partial summary judgment of invalidity was barred after the PTAB issued final written decisions, regardless of when the motion was filed. The defendant filed its motion before the final written decisions were issued, but the court rejected the defendant’s argument that the timing of the motion insulated it from estoppel.

...

Read More

IP Newsflash

October 1, 2025

In a recent final written decision, the PTAB determined that a reference patent was not prior art, despite the petitioner’s post‑filing attempt to correct its petition. While the petitioner argued that it intended to rely on the patent application’s earlier date of publication, both the corrected petition and the expert declaration continued to reference the issued patent rather than the published application.

...

Read More

IP Newsflash

September 30, 2025

The USPTO Director recently granted a petitioner’s request for rehearing of the decision discretionarily denying institution of inter partes review, ultimately vacating the original decision, and referring the petition to the board for an institution decision.

...

Read More

IP Newsflash

September 25, 2025

In considering claims to a method of reducing cardiovascular events, the Federal Circuit held that the term a “clinically proven effective” amount did not render the claims patentable over the prior art. Specifically, the Federal Circuit held that the “clinically proven effective” amount, whether limiting or not, could not be used to distinguish the prior art because the claims also specified the exact amount of the drugs to be administered in the method. The Federal Circuit also rejected patentee’s evidence of unexpected results because that evidence was tied solely to the “clinically proven effective” limitation.

...

Read More

IP Newsflash

September 24, 2025

The Federal Circuit reversed a district court’s denial of judgment as a matter of law on non-infringement, thereby setting aside a $106 million jury verdict, after holding that prosecution history estoppel barred the patentee from asserting infringement under the doctrine of equivalents.

...

Read More

IP Newsflash

September 17, 2025

A magistrate judge in the District of Delaware issued a Report and Recommendation, that found the sole asserted claim was a “single means” claim and therefore invalid for lack of enablement. In reaching that conclusion, the magistrate judge rejected the patentee’s argument that the preamble of the claim disclosed a second element that satisfied the combination requirement of Section 112, paragraph 6 because the preamble simply recited a descriptor of the very apparatus that was the subject of the means-plus-function limitation in the body of the claim. The district court judge presiding over this case has scheduled a hearing to review the magistrate’s ruling.

...

Read More

© 2025 Akin Gump Strauss Hauer & Feld LLP. All rights reserved. Attorney advertising. This document is distributed for informational use only; it does not constitute legal advice and should not be used as such. Prior results do not guarantee a similar outcome. Akin is the practicing name of Akin Gump LLP, a New York limited liability partnership authorized and regulated by the Solicitors Regulation Authority under number 267321. A list of the partners is available for inspection at Eighth Floor, Ten Bishops Square, London E1 6EG. For more information about Akin Gump LLP, Akin Gump Strauss Hauer & Feld LLP and other associated entities under which the Akin Gump network operates worldwide, please see our Legal Notices page.